Medicortex Finland Oy Announces Issuance of a Patent for Brain Injury Biomarker
16.4.2020 09:55:00 EEST | Business Wire | Press release
Medicortex Finland Oy, an innovative biopharmaceutical company focused on the development of diagnostics and drug treatment for mild traumatic brain injury (TBI), today announced that the European Patent Office (EPO) has issued a patent covering company’s new diagnostic kit technology.
“We are extremely pleased with the growth of the patent portfolio related to the TBI testing. This new issuance continues to expand the intellectual property portfolio covering methods to be used for detection of concussion biomarkers. The issuance of this patent is another step in the development of a robust patent portfolio relating to a new strategy to help identify mild TBI” said Dr. Harel Adrian, Chief Executive Officer of Medicortex.
Medicortex is currently developing a rapid diagnostic kit for detection of concussion and mild traumatic brain injury from urine or saliva. The kit is based on specific biomarkers that the company has discovered from body fluids following brain injury. Such a rapid test will fulfill the urgent need to improve the detection of brain injury especially in mild cases – which are potentially harmful but admittedly difficult to diagnose with the contemporary means. The issued patent covers the core technology and method of utilizing glycan-based biomarkers for detection of mild traumatic brain injury, which is presently the company’s main development program.
Medicortex’s patent portfolio comprises of biomarkers for brain injury diagnostics and drug candidates for halting the progression of brain injury. All innovations have been developed by the company. The comprehensive patent coverage secures exclusivity to develop the products, and the company’s strategy is to actively seek new patentable innovations from its biomarker and drug development programs.
About Medicortex
Medicortex Finland Oy is a biotechnology company dedicated to improving the diagnostics and treatment of Traumatic Brain Injury (TBI). Its current focus is on developing biomarker diagnostics to detect the presence of a head injury. The company has the technology to capture biomarkers from urine and saliva and to develop them into an affordable diagnostic tool. Medicortex was established by an Israeli neurobiologist Adrian Harel (Ph.D., MBA) in 2014, and the company is based in Turku, Finland.
Key words: brain injury, head injury, concussion, diagnostics, TBI, early detection, trauma, clinical trial, new patent
Cautionary Note Regarding Forward-Looking Statements
Any statements contained in this press release that do not describe historical facts may constitute forward-looking statements. Medicortex assumes no obligation to, and does not intend to, update any forward-looking statements, whether as a result of new information, future events or otherwise.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20200415005854/en/
Contact information
Medicortex Finland Oy
Dr. Adrian Harel - CEO
Tel. +358 (0) 400 488 817
adrian.harel@medicortex.fi
http://www.medicortex.fi
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Chiesi Group Delivers Solid H1 2026 Performance, Combining Growth, Continued Investment in Innovation and Positive Economic Impact Across Communities9.9.2026 12:00:00 EEST | Press release
Chiesi Group ("Chiesi"), an international research-focused biopharmaceutical company and certified B Corp, today announced its financial results for the six months ended 30 June 2026 ("H1 2026"). Performance across therapeutic areas and regions Chiesi reported revenues of €1.89 billion, representing growth of +3.6% at constant exchange rates (CER) compared with H1 2025. These results do not include the impact of the recent acquisition of KalVista Pharmaceuticals. The Group's growth is supported by continued expansion of its global rare diseases area (+€45m; +9.9% @CER), and sustained performance in neonatology and specialty care therapeutic areas (+6.5% @CER). The respiratory health area remains broadly stable (-0.8% @CER) fueled by the strong growth in our inhaled triple therapy portfolio. Driven by the ongoing execution of its international growth strategy, Chiesi continued to expand its presence in key markets, with particularly strong momentum in the United States (+9.6% @CER), whi
Visa and World Bank Group Announce New Risk-Sharing Initiative to Expand Digital Payments and Financial Inclusion in Emerging Markets9.9.2026 12:00:00 EEST | Press release
Visa (NYSE: V), a global leader in digital payments, and the International Finance Corporation (IFC), a member of the World Bank Group focused on the private sector, are partnering on an innovative risk-sharing initiative designed to help expand financial inclusion by increasing access to digital financial services in emerging markets. Under the agreement, IFC will share credit settlement risk for Visa transactions associated with enrolled financial institutions, enabling these institutions to connect more underbanked consumers and small businesses to digital payments. The facility is expected to support approximately $200 million in risk sharing over five years, with an initial focus on 14 countries in Latin America and the Caribbean and reach approximately 50 financial institutions with below-investment grade ratings. Together, Visa and IFC aim to help financial institutions enable millions more people and small businesses to save, spend, borrow, grow, and participate more fully in t
Ant Group Open-Sources Ling-3.0-flash-Fin for Real-World Financial Workflows9.9.2026 11:36:00 EEST | Press release
Ant Group today announced the open-sourcing of Ling-3.0-flash-Fin at the 2026 Inclusion·Conference on the Bund. Grounded in actual business needs as an open model for real-world financial workflows, this release continues Ant Group's exploration of bringing AI into practical scenarios, focusing on delivering utility and high efficiency for complex tasks. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260908565055/en/ Solving Real-World Challenges Through Efficiency Financial work depends on trustworthy sources, consistent definitions, accurate calculations and auditable outputs. AI in this sector must go beyond simple question-and-answer interactions to navigate dynamic information, complex accounting standards, and stringent compliance requirements. Ling-3.0-flash-Fin was co-developed with leading financial institutions and industry experts to embed professional expertise directly into task definition, data systems, and eva
1NCE adds Data Benchmarking, AI Capabilities and ISO certification9.9.2026 11:00:00 EEST | Press release
1NCE announced a new upgrade of 1NCE Insights and the launch of 1NCE AI. Both expand 1NCE's foundational platform services, giving customers greater intelligence and control over connected device data. The new 1NCE Insights upgrade gives customers access to aggregated benchmark data from 30,000+ deployments. They can compare network usage patterns, battery performance, hardware choices and traffic optimization against real-world peers, enabling faster product development. 1NCE AI provides access to leading AI models through a unified API gateway, eliminating vendor fragmentation. The service is Germany-hosted and fully GDPR-compliant, with 1NCE's Token service enabling customers to manage and optimize AI token costs across all models. Data security is foundational. Customer-collected data belongs to the customer. 1NCE Insights uses only anonymized, aggregated network data. 1NCE's infrastructure is ISO/IEC 27001:2022 certified by TÜV Rheinland, valid through 2029. "Our platform gives cu
FinXP Partners with Thredd to Strengthen Multi-Region Card Issuing Capabilities9.9.2026 10:00:00 EEST | Press release
FinXP, a European payment infrastructure provider, has partnered with Thredd, the AI-first issuer processing platform, to strengthen FinXP’s card issuing capabilities and support the next phase of its embedded finance offering. The partnership with Thredd will enable FinXP to enhance its debit card programmes with a modern issuer-processing stack, supporting tokenisation, provisioning, risk and fraud prevention, card controls, and automated back-office operations. FinXP will retain control of its own ledger and programme strategy, while Thredd will provide the programme infrastructure needed to support secure, scalable and flexible card issuing across multiple regions. FinXP has been issuing cards for five years and already supports businesses with accounts, payments, collections, payouts, card issuing and embedded finance solutions. The partnership with Thredd marks a further step in FinXP’s strategy to provide scalable, multi-region payment infrastructure to fintechs, platforms and b
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom